Patents by Inventor Maya Margalit
Maya Margalit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230090114Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the reduction of total body weight, reduction of body fat content, and/or reduction of BMI of the subject in need thereof are provided.Type: ApplicationFiled: January 29, 2021Publication date: March 23, 2023Inventors: Mordechay ROSENSTOCK, Maya MARGALIT
-
Publication number: 20210260100Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20200281961Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: February 26, 2020Publication date: September 10, 2020Applicant: ENZO THERAPEUTICS, INC.Inventors: Yaron ILAN, Maya MARGALIT, Ari ZIMRAN
-
Patent number: 10639324Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: October 30, 2018Date of Patent: May 5, 2020Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20190060353Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: October 30, 2018Publication date: February 28, 2019Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Patent number: 9907810Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: July 12, 2017Date of Patent: March 6, 2018Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit
-
Publication number: 20180042951Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: July 12, 2017Publication date: February 15, 2018Applicant: ENZO THERAPEUTICS, INC.Inventors: YARON ILAN, MAYA MARGALIT
-
Publication number: 20180042959Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: June 12, 2017Publication date: February 15, 2018Applicant: ENZO THERAPEUTICS, INC.Inventors: YARON ILAN, MAYA MARGALIT, ARI ZIMRAN
-
Publication number: 20180036326Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: October 11, 2017Publication date: February 8, 2018Applicant: ENZO THERAPEUTICS, INC.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran, Elazar Rabbani, Dean L. Engelhardt
-
Patent number: 9744185Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: March 17, 2006Date of Patent: August 29, 2017Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit
-
Patent number: 9717754Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: GrantFiled: September 30, 2003Date of Patent: August 1, 2017Assignee: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
-
Publication number: 20170042921Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: October 11, 2016Publication date: February 16, 2017Applicant: Enzo Therapeutics, Inc.Inventors: Yaron ILAN, Maya Margalit, Ari Zimran, Elazar Rabbani, Dean L. Engelhardt
-
Publication number: 20070010483Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: March 17, 2006Publication date: January 11, 2007Inventors: Yaron IIan, Maya Margalit
-
Publication number: 20060257932Abstract: The oral administration of a drug results in the safe and effective treatment of individuals with moderate to severe Crohn's disease. Additionally, the identification and measurement of the levels of certain markers may be used to create an immune profile for the prediction of clinical responses to the drug. These measurements may also be developed into surrogate markers for the response to the treatment of the disease.Type: ApplicationFiled: March 16, 2006Publication date: November 16, 2006Inventors: Yaron Ilan, Maya Margalit
-
Publication number: 20050069546Abstract: The present invention relates to a method for the treatment of immune-related or immune-mediated disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NKT cell population in said subject by suitable means, said manipulation of the NKT cell population resulting in modulation of the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NKT cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NKT cells, such that the educated NKT cells have the capability to modulate the Th1/Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related or immune-mediated disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NKT cell.Type: ApplicationFiled: September 30, 2003Publication date: March 31, 2005Inventors: Yaron Ilan, Maya Margalit, Eran Elinav
-
Publication number: 20040171527Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171557Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.Type: ApplicationFiled: September 30, 2003Publication date: September 2, 2004Inventors: Yaron Iian, Maya Margalit, Ari Zimran
-
Publication number: 20040171526Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171528Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: December 10, 2003Publication date: September 2, 2004Applicant: Enzo Therapeutics, Inc.Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran
-
Publication number: 20040171522Abstract: The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, Crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones. Treatment can be carried by introduction of the intermediary metabolite into the afflicted subject or by a reagent that when administered leads to elevated levels. The treatment regimen can be in vivo or ex vivo.Type: ApplicationFiled: February 27, 2003Publication date: September 2, 2004Inventors: Yaron Ilan, Maya Margalit, Dean L. Engelhardt, Elazar Rabbani, Ari Zimran